Bristol Myers Squibb (CELG-RI) Capital Expenditures (2009 - 2026)

Bristol Myers Squibb has disclosed Capital Expenditures across 18 years of filings, most recently posting $347.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 33.46% year-over-year to $347.0 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 14.22% YoY), while the FY2025 annual figure was $1.3 billion, up 5.05% from the prior year.
• Capital Expenditures slipped to $347.0 million in Q1 2026, from $370.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for CELG-RI reached as high as $378.0 million in Q4 2024 and fell as low as $247.0 million in Q3 2022.
• The 5-year median for Capital Expenditures is $320.0 million (2025), against an average of $307.8 million.
• The widest YoY moves for Capital Expenditures: up 46.24% in 2022, down 8.52% in 2022.
• A 5-year view of Capital Expenditures shows it stood at $346.0 million in 2022, then decreased by 4.62% to $330.0 million in 2023, then increased by 14.55% to $378.0 million in 2024, then declined by 2.12% to $370.0 million in 2025, then dropped by 6.22% to $347.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $347.0 million, $370.0 million, and $320.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.